DrugPatentWatch Database Preview
GOCOVRI Drug Profile
When do Gocovri patents expire, and what generic alternatives are available?
Gocovri is a drug marketed by Adamas Pharma and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in GOCOVRI is amantadine hydrochloride. There are seven drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.
Summary for GOCOVRI
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 110 |
| Patent Applications: | 1,448 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for GOCOVRI |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GOCOVRI |
| DailyMed Link: | GOCOVRI at DailyMed |
Medical Subject Heading (MeSH) Categories for GOCOVRI
US Patents and Regulatory Information for GOCOVRI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GOCOVRI
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 137 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for GOCOVRI
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2017019874 | ➤ Sign Up |
| Japan | 2013512919 | ➤ Sign Up |
| European Patent Office | 2623099 | ➤ Sign Up |
| Australia | 2015202356 | ➤ Sign Up |
| Japan | 5885668 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2011069010 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
